Hims & Hers Health (HIMS) has emerged as a disruptive force in telehealth, leveraging technology and personalization to address highly-personal health conditions while achieving scalable profitability ...

Hims & Hers Health stock is trading -39.24% below its average target price of $44.82 after marking a 1.0% during today's ...

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

Patients who received Lilly’s pill did not show signs of liver damage, the company said. Liver side effects scuttled Pfizer’s ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an ...

BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...